Türeci Ö - Search Results

1

Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial.

Thomas SJ, Perez JL, Lockhart SP, Hariharan S, Kitchin N, Bailey R, Liau K, Lagkadinou E, Türeci Ö, Şahin U, Xu X, Koury K, Dychter SS, Lu C, Gentile TC, Gruber WC. Thomas SJ, et al. Among authors: tureci o. Vaccine. 2022 Mar 1;40(10):1483-1492. doi: 10.1016/j.vaccine.2021.12.046. Epub 2021 Dec 24. Vaccine. 2022. PMID: 35131133 Free PMC article. Clinical Trial.

2

Multiple splice variants of lactate dehydrogenase C selectively expressed in human cancer.

Koslowski M, Türeci O, Bell C, Krause P, Lehr HA, Brunner J, Seitz G, Nestle FO, Huber C, Sahin U. Koslowski M, et al. Among authors: tureci o. Cancer Res. 2002 Nov 15;62(22):6750-5. Cancer Res. 2002. PMID: 12438276

3

Identification of tumor-associated autoantigens with SEREX.

Türeci O, Usener D, Schneider S, Sahin U. Türeci O, et al. Methods Mol Med. 2005;109:137-54. doi: 10.1385/1-59259-862-5:137. Methods Mol Med. 2005. PMID: 15585919

4

The human X chromosome is enriched for germline genes expressed in premeiotic germ cells of both sexes.

Koslowski M, Sahin U, Huber C, Türeci O. Koslowski M, et al. Among authors: tureci o. Hum Mol Genet. 2006 Aug 1;15(15):2392-9. doi: 10.1093/hmg/ddl163. Epub 2006 Jun 29. Hum Mol Genet. 2006. PMID: 16809397

5

Identification of new claudin family members by a novel PSI-BLAST based approach with enhanced specificity.

Wu J, Helftenbein G, Koslowski M, Sahin U, Tureci O. Wu J, et al. Among authors: tureci o. Proteins. 2006 Dec 1;65(4):808-15. doi: 10.1002/prot.21218. Proteins. 2006. PMID: 17022085

6

In silico strategy for detection of target candidates for antibody therapy of solid tumors.

Helftenbein G, Koslowski M, Dhaene K, Seitz G, Sahin U, Türeci O. Helftenbein G, et al. Among authors: tureci o. Gene. 2008 May 15;414(1-2):76-84. doi: 10.1016/j.gene.2008.02.009. Epub 2008 Feb 19. Gene. 2008. PMID: 18358640

7

Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development.

Sahin U, Koslowski M, Dhaene K, Usener D, Brandenburg G, Seitz G, Huber C, Türeci O. Sahin U, et al. Among authors: tureci o. Clin Cancer Res. 2008 Dec 1;14(23):7624-34. doi: 10.1158/1078-0432.CCR-08-1547. Clin Cancer Res. 2008. PMID: 19047087

8

Selective activation of tumor growth-promoting Ca2+ channel MS4A12 in colon cancer by caudal type homeobox transcription factor CDX2.

Koslowski M, Türeci O, Huber C, Sahin U. Koslowski M, et al. Among authors: tureci o. Mol Cancer. 2009 Sep 25;8:77. doi: 10.1186/1476-4598-8-77. Mol Cancer. 2009. PMID: 19781065 Free PMC article.

9

Determinants of intracellular RNA pharmacokinetics: Implications for RNA-based immunotherapeutics.

Kuhn AN, Diken M, Kreiter S, Vallazza B, Türeci Ö, Sahin U. Kuhn AN, et al. Among authors: tureci o. RNA Biol. 2011 Jan-Feb;8(1):35-43. doi: 10.4161/rna.8.1.13767. Epub 2011 Jan 1. RNA Biol. 2011. PMID: 21289486

10

Tumor vaccination using messenger RNA: prospects of a future therapy.

Kreiter S, Diken M, Selmi A, Türeci Ö, Sahin U. Kreiter S, et al. Among authors: tureci o. Curr Opin Immunol. 2011 Jun;23(3):399-406. doi: 10.1016/j.coi.2011.03.007. Epub 2011 Apr 13. Curr Opin Immunol. 2011. PMID: 21497074 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

193 results

Search Page